| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Cisplatin | GDSC1000 | pan-cancer | AAC | 0.0099 | 0.8 |
| mRNA | ML162 | CTRPv2 | pan-cancer | AAC | -0.01 | 0.8 |
| mRNA | foretinib | GDSC1000 | pan-cancer | AAC | -0.0093 | 0.8 |
| mRNA | KH-CB19 | CTRPv2 | pan-cancer | AAC | -0.014 | 0.8 |
| mRNA | Bortezomib | GDSC1000 | pan-cancer | AAC | -0.014 | 0.8 |
| mRNA | temsirolimus | GDSC1000 | pan-cancer | AAC | 0.0096 | 0.8 |
| mRNA | ML203 | CTRPv2 | pan-cancer | AAC | 0.011 | 0.8 |
| mRNA | BRD-K29313308 | CTRPv2 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | regorafenib | CTRPv2 | pan-cancer | AAC | 0.011 | 0.8 |
| mRNA | BRD-K34485477 | CTRPv2 | pan-cancer | AAC | -0.022 | 0.8 |